Actively Recruiting
Evaluating Lumateperone for Treating Irritability in Children and Teens with Autism Spectrum Disorder in a Randomized, Placebo-Controlled Study
Led by Intra-Cellular Therapies, Inc. · Updated on 2026-11-03
160
Participants Needed
41
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating lumateperone in a study involving children and teenagers aged 5 to 17 years who have irritability linked to Autism Spectrum Disorder ASD. This is a randomized, double-blind, placebo-controlled trial aimed at assessing the safety and effectiveness of lumateperone in this pediatric population. Diagnosis is confirmed using DSM-5-TR criteria and the K-SADS-PL assessment tool. Participants will be randomly assigned to one of three groups to receive either a high dose of lumateperone 42 mg, a low dose of lumateperone 21 mg, or a placebo. The treatment is taken orally once daily during a 6-week double-blind period. The study includes an initial screening phase lasting up to 14 days, and a safety follow-up visit occurs about one week after the last dose. During the study, participants will attend visits for screening, treatment, and safety follow-up. Researchers will evaluate irritability using the Aberrant Behavior Checklist - Irritability subscale at 6 weeks, along with the Clinical Global Impression-Severity scale. Safety monitoring will be conducted throughout, and total participation spans screening, 6 weeks of treatment, and a 1-week follow-up period.
CONDITIONS
Brief Title
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients
Research Team
S
Study Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here